Discover our strategy
Stay Ahead with Treos Bio Updates
Subscribe to our newsletter for company updates!
Why Investors Choose Treos Bio
$8 Billion Opportunity in Colorectal Cancer Alone, Where Current Immunotherapies Fail
Delivers True Precision Medicine Across a Diverse Patient Population, Without Sacrificing Accessibility or Expensive Manufacturing
Active Collaborations with Mayo Clinic to Run Phase II Trials in Conjunction with Charite Clinic Berlin
Clinical Validation & Partnerships in Place
Ready to Learn More?
Join a growing base of investors who engage with Treos Bio. Connect with our team or access our latest investor materials today.